ReviewCell death & disease2025
Immune cells dying from ferroptosis: mechanisms and therapeutic opportunities.
Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A transferrin receptor-targeted liposome for iron metabolism regulation-augmented photodynamic therapy in glioblastoma.Bioactive materials · 2027Article
- Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2026Review
- Natural products mediate ferroptosis and immune microenvironment-linked sensitization in osteosarcoma: from chemotherapy resistance to combined therapeutic transformation.Molecular diversity · 2026Review
- Metabolic Mechanisms of Hexavalent Chromium-Induced Splenic Immune Injury via Oxidative Stress and Ferroptosis Pathways in New Zealand Rabbits.Metabolites · 2026Article
- Sympathetic signaling activation alleviated acute respiratory distress syndrome via the HDC/SLC7A11 axis in lipopolysaccharide-induced macrophages.Cell death discovery · 2026Article
- The Treg-cell death axis in lung cancer: implications for immune evasion and novel therapeutic strategies.Molecular cancer · 2026Review
- "Ferroptosis-immune" cycle: Research progress of tumor microenvironment responsive nanomaterials in the treatment of pancreatic cancer.iScience · 2026Review
- Ferroptosis shapes ILC2 responses in inflammatory bowel disease.Cellular & molecular immunology · 2026Article
- Ferroptosis in Recurrent Vulvovaginal Candidiasis Through Integrated Bioinformatics and Experimental Validation.Antioxidants (Basel, Switzerland) · 2026Article
- Immune Aging as a Failure of Programmed Cell Death Coordination.International journal of molecular sciences · 2026Review
- The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes.Frontiers in oncology · 2026Review
- GPX4 Defines an Immune-Cold Phenotype and Poor Prognosis in Resected Lung Adenocarcinoma.Oncology research · 2026Article
- Advances in ferroptosis mechanisms and therapeutic potential in head and neck squamous cell carcinoma.Frontiers in cell and developmental biology · 2026Review
- The interplay mechanisms between gut microbiota and ferroptosis in inflammatory bowel disease.Frontiers in immunology · 2026Review
- Metabolic control of ferroptosis in cancer: lipid dependencies as therapeutic vulnerabilities.Frontiers in oncology · 2026Review
- Redox Network Dysfunction: Integrating Ferroptosis and Cuproptosis Across Human Diseases.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review explores the intricate regulation of ferroptosis through diverse pathways and related metabolism, focusing on the mechanisms of ferroptosis in diverse immune cells, including granulocytes, macrophages, dendritic cells, T/B lymphocytes, natural killer/ innate lymphoid cells, under conditions of iron metabolism imbalance and lipid peroxidation accumulation, highlighting their pivotal roles in the dynamic regulation of immune microenvironments. Furthermore, the review summarizes the therapeutic potential of targeting ferroptosis pathways in tumor immunity, pathogen infections, inflammation, and autoimmune diseases. It systematically compiles recent advances in ferroptosis-related drugs and small molecule inhibitors, while proposing novel therapeutic strategies through intervention in ferroptosis-immune interactions for immune-related disorders. Additionally, this review summarizes the mechanisms of epigenetic regulation of ferroptosis. As a core enzyme in epigenetic regulation, Enhancer of zeste homolog 2 (EZH2) serves as a pivotal node linking epigenetic regulation, tumorigenesis, immune control, and ferroptosis, providing novel therapeutic insights for anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.